EDISCIENCES

ABSTRACT

Anti-HER2 therapies, especially when combined with chemothe- rapy, have dramatically improved survival in early and advance and metastatic BC. Although standardized guidelines for the treatment of HER-2+ Breast cancer (BC) exist, few studies have identi ed treatment patterns and opportunities to improve care among edlerly patients. There is a common agreement that older, t patients can bene t from cancer treatments as younger patients, so we would need best of all screening which wolud identify the t and un- t patients. A recent updated recommendations regarding the mana- gement of older patients with breast cancer suggest that: adjuvant chemotherapy along with one year of trastuzumab is recommended as a standard approach in t older patients Trastuzumab, preferred regimens options anthra free. Shorter corse of anti HER 2 therapy can be considered for older patients with small, node –negative tu- mours or if cardiac failure. Although evidence is scarce, the use of single-drug trastuzumab without chemotherapy, but with endocrine therapy if hormone sensitive, can be appropriate in susceptible and frail patients. Pertuzumab can be added only in high risk and t patients in MBC Her-2 positive, t patients should be treated in st line with CLEOPATRA-like regimen and second line with emilia regimen. Un t or frail patients should be considered for alternative, strategies, including endcrine therapy+ dual blockade, dual blocka- de alone and use of less toxic chemotherapy.